Early experience with Watson for Oncology: a clinical decision-support system for prostate cancer treatment recommendations
- 25 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in World Journal of Urology
- Vol. 39 (2), 407-413
- https://doi.org/10.1007/s00345-020-03214-y
Abstract
Purpose Urological oncologists have difficulty providing optimal personalized care due to rapid alterations in scientific research results, medical advancements, and treatment guidelines. IBM’s Watson for Oncology (WFO) is an artificial intelligence clinical decision-support system that assists oncologists with evidence-based treatment recommendations. In the present study, we examined the level of concordance between the treatment recommendations for prostate cancer according to WFO and the actual treatments that the patients received in the department of urology. Methods We enrolled 201 patients who received prostate cancer treatment between January 2018 and June 2018. WFO provided treatment recommendations using clinical data in three categories: recommended, for consideration, and not recommended. These were compared with the actual treatments received by patients. Prostate cancer treatments were considered concordant if the received treatments were included in the “recommended” or “for consideration” categories by WFO. Results The patients’ mean age was 71.2 years. There were 60 (29.9%) and 114 (56.7%) patients with an Eastern Cooperative Oncology Group (ECOG) performance score ≥ 1 and non-organ confined disease (stage III/IV), respectively. The overall prostate cancer treatment concordance rate was 73.6% (“recommended”: 53.2%; “for consideration”: 20.4%). An ECOG performance score ≥ 1 and older age (≥ 75 years) were significantly associated with discordance (p = 0.001 and p = 0.026, respectively) on multivariate analysis. Conclusion In the present study, the treatment recommendations by WFO and the actual received treatments in the department of urology showed a relatively high concordance rate in prostate cancer patients.Keywords
Funding Information
- Chonnam National University Hwasun Hospital Institute for Biomedical Science (HCRI18015-1)
This publication has 23 references indexed in Scilit:
- Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinomaCancer, 2019
- Concordance Rate between Clinicians and Watson for Oncology among Patients with Advanced Gastric Cancer: Early, Real-World Experience in KoreaCanadian Journal of Gastroenterology and Hepatology, 2019
- Assessing Concordance With Watson for Oncology, a Cognitive Computing Decision Support System for Colon Cancer Treatment in KoreaJCO Clinical Cancer Informatics, 2018
- Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor boardAnnals Of Oncology, 2018
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerEuropean Urology, 2017
- Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancerAsia-Pacific Journal of Clinical Oncology, 2014
- Burnout and Career Satisfaction Among US OncologistsJournal of Clinical Oncology, 2014
- Multidisciplinary teams in cancer care: are they effective in the UK?The Lancet Oncology, 2006
- Expert Systems ResearchScience, 1983